Medical Care Technologies (OTC PINK:MDCE) Provides Additional Details Regarding MDCE Melanoma Scan Beta Imaging Platform

Rhea-AI Summary

Medical Care Technologies (OTC PINK:MDCE) outlined design and development details for its MDCE Melanoma Scan Beta imaging platform. The beta-stage AI-assisted body-map application focuses on organizing skin images and supporting longitudinal visual tracking while remaining a non-diagnostic, pre-screening tool without FDA review or clearance.

AI-generated analysis. Not financial advice.

News Market Reaction – MDCE

-33.33%

1 alert

-33.33% News Effect

On the day this news was published, MDCE declined 33.33%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Company discusses AI-assisted body-map monitoring architecture and long-term imaging technology development initiatives

MESA, AZ / ACCESS Newswire / May 28, 2026 / Medical Care Technologies Inc. (OTC PINK:MDCE) ("MDCE" or the "Company"), a technology company focused on AI-powered imaging and wellness applications, today provided additional details regarding the design framework and development objectives of its MDCE Melanoma Scan Beta platform.

The beta-stage platform is being developed as an AI-assisted imaging and body-map monitoring application intended to support image organization and long-term visual tracking workflows. The platform incorporates an interactive body-map interface designed to allow users to catalog, compare, and monitor visible skin images over time within a centralized monitoring environment.

The Company stated that one of the primary development goals surrounding the MDCE Melanoma Scan Beta platform involves creating a structured longitudinal imaging framework intended to assist users in organizing image history and tracking visible changes through repeat imaging workflows.

Medical Care Technologies noted that the platform remains in beta-stage development and continues undergoing internal refinement related to user experience optimization, imaging workflow consistency, platform infrastructure, and long-term AI development initiatives.

"Our focus is centered around building intelligent imaging technologies designed to support future monitoring and wellness-oriented applications," stated Marshall Perkins. "We believe longitudinal imaging and AI-assisted image organization technologies may represent an important future category within preventative wellness and digital imaging platforms."

The Company further stated that the MDCE Melanoma Scan Beta platform represents part of its broader long-term strategy involving AI-assisted imaging technologies and scalable image analysis infrastructure.

Medical Care Technologies emphasized that the current beta platform is an early-stage pre-screening technology currently under development and evaluation. The MDCE Melanoma Scan Beta platform is not intended to diagnose, treat, cure, or prevent any disease or medical condition and has not yet been reviewed or cleared by the U.S. Food and Drug Administration.

The Company expects to continue providing shareholders with future updates regarding testing initiatives, platform refinement efforts, AI infrastructure development, and long-term strategic evaluation pathways related to the MDCE Melanoma Scan Beta platform.

About Medical Care Technologies Inc.

Medical Care Technologies Inc. is a technology company focused on AI-powered consumer applications, imaging technologies, wellness platforms, and digital innovation initiatives. The Company's portfolio includes AI-assisted imaging technologies, wellness applications, authentication technologies, and consumer-focused software platforms.

Investor / Media Contact:
Medical Care Technologies Inc.
1910 S Stapley Drive
Suite 221
Mesa, AZ 85204
+1 480-645-0750
info@medicalcaretechnologies.com

X: https://x.com/medicalcaretech
Website: https://medicalcaretechnologies.com/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include, but are not limited to, statements regarding future development initiatives, AI imaging technologies, testing plans, commercialization opportunities, strategic growth objectives, and platform expansion initiatives. The Company undertakes no obligation to publicly update forward-looking statements except as required by applicable law.

SOURCE: Medical Care Technologies Inc.

View the original press release on ACCESS Newswire

FAQ

What is the MDCE Melanoma Scan Beta imaging platform by Medical Care Technologies (OTC PINK:MDCE)?

The MDCE Melanoma Scan Beta is an AI-assisted imaging and body-map monitoring application for organizing and tracking visible skin images. According to Medical Care Technologies, it supports centralized image cataloging and comparison to help users monitor visual changes over time within structured workflows.

Does the MDCE Melanoma Scan Beta platform diagnose melanoma or other skin cancers for MDCE users?

No, the MDCE Melanoma Scan Beta platform is not intended to diagnose, treat, cure, or prevent any disease. According to Medical Care Technologies, it functions as an early-stage pre-screening and monitoring tool focused on image organization and longitudinal tracking of visible skin features.

Is the MDCE Melanoma Scan Beta imaging platform FDA approved or cleared as of May 28, 2026?

The MDCE Melanoma Scan Beta platform has not been reviewed or cleared by the U.S. Food and Drug Administration. According to Medical Care Technologies, it remains in beta-stage development and is still under internal evaluation and refinement for future monitoring and wellness-oriented imaging applications.

What AI-assisted features are included in the MDCE Melanoma Scan Beta body-map monitoring platform (MDCE)?

The MDCE Melanoma Scan Beta uses AI-assisted technologies to help organize and track visible skin images over time. According to Medical Care Technologies, it integrates an interactive body-map interface that supports image cataloging, comparison, and structured longitudinal imaging workflows in a centralized monitoring environment.

What development stage is the MDCE Melanoma Scan Beta platform in for Medical Care Technologies shareholders?

The MDCE Melanoma Scan Beta platform is currently in beta-stage development undergoing internal refinement and evaluation. According to Medical Care Technologies, efforts focus on user experience, workflow consistency, platform infrastructure, and long-term AI initiatives aligned with its broader imaging and wellness technology strategy.

How does the MDCE Melanoma Scan Beta support longitudinal imaging and skin change tracking for MDCE users?

The MDCE Melanoma Scan Beta is designed to create a structured longitudinal imaging framework for repeat image capture. According to Medical Care Technologies, it enables users to organize historical images and monitor visible changes over time using AI-assisted body-map workflows in a centralized environment.

What future updates does Medical Care Technologies (MDCE) plan for the Melanoma Scan Beta platform?

Medical Care Technologies plans to continue updating shareholders on testing, refinement, and AI infrastructure development for the MDCE Melanoma Scan Beta platform. According to the company, future communications will address ongoing evaluation pathways and long-term strategic considerations for its AI-assisted imaging technologies.